The dysregulation of ECM has been found to be related to the development of AD in several ways, including the triggering/inhibition of Aβ aggregation, interaction with tau protein, relieving oxidative stress and reducing inflammatory response (Sun et al., 2021). Here, MAPT is linked to Alzheimer disease.